stockportfolio.pro
Stocks / TLX vs VKTX
TLX vs VKTX
Telix Pharmaceuticals Limited and Viking Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Telix Pharmaceuticals Limited (TLX) | Viking Therapeutics, Inc. (VKTX) | |
|---|---|---|
| Market cap | $3.2B | $3.2B |
| Revenue (latest FY) | $803.79M | $0 |
| Net income (latest FY) | $-7.13M | $-359.64M |
| Revenue growth (5y CAGR) | 94.7% | — |
| Net margin | -0.9% | — |
| Return on equity | -1.7% | -56.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | — | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open TLX — free Open VKTX — freeFrequently asked questions
Which is bigger, TLX or VKTX?
Viking Therapeutics, Inc. is larger by market capitalization — $3.2B versus $3.2B.
Which grows faster, TLX or VKTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.